PfizerRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
| Program / Trial | Phase / Date | Outcome |
|---|---|---|
| Lotiglipron (PF-07081532) | Phase 2; 2022-2023 | Oral small-molecule GLP-1 RA; once-daily; advanced into Phase 2 obesity + T2D cohorts; June 2023 discontinuation due to dose-dependent liver enzyme elevations observed during the Phase 2 program (ALT >3x ULN in multiple subjects) |
| Danuglipron BID (PF-06882961) Phase 1 | Phase 1; 2019-2020 | Oral small-molecule GLP-1 RA; twice-daily formulation; dose-response demonstrated; supported Phase 2 advancement |
| Danuglipron BID Phase 2a (T2D) | Phase 2a; 2021-2022 | Dose-related HbA1c reduction in T2D cohort; supported advancement to obesity Phase 2b; GI tolerability flagged as the limiting factor early |
| Danuglipron BID Phase 2b (obesity, 32 weeks) | Phase 2b; Dec 2023 readout | Up to 12.9% placebo-adjusted weight loss at 32 weeks (top 200mg BID dose). 38.5% overall adverse-event-related discontinuation (31.6% gastrointestinal; ~60% in the top 200mg BID arm) due to nausea, vomiting, and diarrhea. No ALT elevations >5x ULN were observed in this trial. Pfizer chose to discontinue the BID formulation and pivot to a once-daily reformulation |
| Danuglipron QD Phase 1 (reformulation) | Phase 1; 2024-2025 | Once-daily extended-release reformulation; pharmacokinetic profile supported lower peak concentrations to improve GI tolerability; April 2025 discontinuation after a single subject experienced asymptomatic but clinically meaningful liver enzyme elevation, leading Pfizer to end the entire danuglipron program |
| Cumulative R&D spend (estimated) | 2018-2025 | Pfizer does not disclose program-level R&D; analyst estimates put cumulative danuglipron + lotiglipron development cost at ~$300-500M including Phase 2 trials, manufacturing scale-up work, and discontinued Phase 3 prep. The hepatotoxicity signal in two unrelated chemotypes raised concerns about a possible class-wide oral GLP-1 RA liver-safety question (later complicated by competitor LLY orforglipron + GPCR aleniglipron Phase 2 data, which did not replicate the signal) |
| Strategic response: Metsera acquisition | Nov 2025 | Pfizer completed its acquisition of Metsera (NY obesity biotech) on November 13, 2025 at $65.60/share (~$7.0B upfront) plus a CVR of up to $20.65/share (up to $86.25/share, ~$10B total), after a bidding contest with Novo Nordisk. Metsera's lead assets are injectable GLP-1 (MET-097i, entering Phase 3) and injectable amylin (MET-233i, Phase 1). The acquisition is Pfizer's re-entry into obesity and the replacement for the discontinued danuglipron program |
| Strategic response: Sciwind ecnoglutide partnership | Feb 2026 | Pfizer China obtained exclusive Mainland China commercialization rights to ecnoglutide (Sciwind's injectable cAMP-biased GLP-1, NMPA-approved for type 2 diabetes in January 2026), worth up to $495M, announced February 24, 2026; Sciwind remains the marketing authorization holder. Part of Pfizer's broader obesity/metabolic push alongside the Metsera acquisition |
| Editorial. What this means for Pfizer | Strategic context | Pfizer is now 5+ years behind LLY + NVO in the obesity market with no commercial-stage internal program. The Metsera assets are 4-6 years from a potential launch. The discontinuation history is a cautionary case study in oral GLP-1 RA development: two independent chemotypes from one company both produced liver-safety signals, while competitors (LLY orforglipron, GPCR aleniglipron) did not. The post-mortem question of whether the danuglipron + lotiglipron liver findings were idiosyncratic or class-related remains unresolved publicly |
| Asset / Mechanism | Phase / Stage | Strategic Positioning |
|---|---|---|
| MET-097i (injectable GLP-1 receptor agonist) | Phase 2 complete; entering Phase 3 | Weekly-and-monthly subcutaneous injectable GLP-1 RA; the lead Metsera asset and Pfizer's primary obesity re-entry vehicle; positioned vs NVO semaglutide + LLY tirzepatide, and as the backbone for combination with MET-233i |
| MET-233i (injectable amylin analog) | Phase 1 (monotherapy + combination) | Monthly subcutaneous injectable amylin analog; mechanistically complementary to GLP-1; developed as monotherapy and in combination with MET-097i; competes with NVO's amylin programs (cagrilintide, amycretin) |
| Oral + preclinical pipeline | Earlier-stage / preclinical | Metsera also carries earlier-stage oral GLP-1 and additional incretin/amylin candidates plus preclinical discovery programs; pipeline depth was part of the acquisition rationale |
| Deal economics (final, completed Nov 13, 2025) | Up to ~$10B | $65.60/share cash (~$7.0B enterprise value) upfront + up to $20.65/share CVR tied to three clinical and regulatory milestones (up to $86.25/share total). The final terms followed a bidding contest with Novo Nordisk that raised Pfizer's original September 22, 2025 offer |
| Sciwind ecnoglutide partnership (China) | Mainland China commercialization; Feb 2026 | Pfizer China obtained exclusive Mainland China commercialization rights to ecnoglutide (Sciwind's injectable cAMP-biased GLP-1, NMPA-approved for type 2 diabetes January 2026) in a deal worth up to $495M announced February 24, 2026; Sciwind remains the marketing authorization holder. Secondary to the Metsera asset base |
| Manufacturing requirements | Capacity build-out post-deal | Pfizer's internal obesity manufacturing capacity is minimal post-danuglipron; Metsera's Phase 3 scale-up and future commercial launch will require new injectable peptide manufacturing investment (analyst estimates ~$1-2B capex over 2026-2028) |
| Editorial. Why this matters | Strategic context | The Metsera assets put Pfizer back in the obesity race but at a delayed timeline versus LLY and NVO. Pfizer's ~$10B headline price reflects the scarcity of clinical-stage obesity assets available for acquisition and the intensity of the Novo Nordisk bidding contest. The marquee question is whether Pfizer can compress the development timeline via parallel Phase 2 + Phase 3 starts and a competitive injectable combination profile |
Charles Pfizer and Charles Erhart found Charles Pfizer & Company in Brooklyn. The vaccines franchise (Prevnar, Comirnaty, Abrysvo) sits on this 19th-century chemical house.
FDA licenses Prevnar 13 (24 Feb 2010), the 13-valent successor to Prevnar 7. This is the core of the $6.494B 2025 Prevnar family.
FDA EUA for Comirnaty with BioNTech. The APA era starts. Comirnaty is still Pfizer's number-four product in 2025 at $4.367B.
Comirnaty receives full US BLA, first COVID vaccine to leave emergency use.
FDA approves Abrysvo for adults, the same week as GSK Arexvy. Abrysvo later adds the only maternal RSV indication (Aug 2023).
FDA approves Abrysvo for maternal RSV at 32 to 36 weeks. Competes with infant mAbs for the same prevention budget. 2025 sales $1.033B.
Novavax licenses Matrix-M adjuvant to Pfizer. Adjuvant becomes a cash story separate from Nuvaxovid volumes.